Literature DB >> 20573419

Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells.

Valentina Salvi1, Daniela Bosisio, Stefania Mitola, Laura Andreoli, Angela Tincani, Silvano Sozzani.   

Abstract

Plasmacytoid dendritic cells (PDC) represent the main type I interferon (IFN-I) producing cells. Emerging evidence supports a role for IFN-I in autoimmune diseases. Given the central role of PDC in the pathogenesis of systemic lupus erythematosus (SLE), we investigated the effect of Trichostatin A (TSA), a prototypic histone deacetylase inhibitor, on PDC activation. TSA inhibited the production of IFN-I, TRAIL and of the pro-inflammatory cytokines TNFalpha and IL-6 by CpG-activated PDC. These effects were associated with the inhibition of IFN Regulatory Factor (IRF)-7 nuclear translocation. Furthermore, TSA was also effective in inhibiting the production of IFNalpha by PDC cultured in vitro in the presence of serum obtained from SLE patients. This study describes a new level of regulation of immune responses by histone deacetylase inhibitors and defines the molecular basis for new strategies to be exploited in the treatment of autoimmune diseases. Copyright 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573419     DOI: 10.1016/j.imbio.2010.05.023

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  14 in total

1.  Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection.

Authors:  Bryan C Mounce; Wadzanai P Mboko; Adam J Kanack; Vera L Tarakanova
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

Review 2.  DNA methylation in systemic lupus erythematosus.

Authors:  Christian M Hedrich; Katrin Mäbert; Thomas Rauen; George C Tsokos
Journal:  Epigenomics       Date:  2016-11-25       Impact factor: 4.778

Review 3.  Targeting interferons in systemic lupus erythematosus: current and future prospects.

Authors:  Alexis Mathian; Miguel Hie; Fleur Cohen-Aubart; Zahir Amoura
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

Review 4.  Epigenetic involvement in etiopathogenesis and implications in treatment of systemic lupus erythematous.

Authors:  Arron Munggela Foma; Saeed Aslani; Jafar Karami; Ahmadreza Jamshidi; Mahdi Mahmoudi
Journal:  Inflamm Res       Date:  2017-07-24       Impact factor: 4.575

Review 5.  HDAC inhibition in lupus models.

Authors:  Christopher M Reilly; Nicole Regna; Nilamadhab Mishra
Journal:  Mol Med       Date:  2011-02-11       Impact factor: 6.354

6.  Potentiation and tolerance of toll-like receptor priming in human endothelial cells.

Authors:  Stephen R Koch; Fred S Lamb; Judith Hellman; Edward R Sherwood; Ryan J Stark
Journal:  Transl Res       Date:  2016-08-08       Impact factor: 7.012

7.  Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7.

Authors:  Valentina Salvi; Veronica Gianello; Sara Busatto; Paolo Bergese; Laura Andreoli; Ugo D'Oro; Alessandra Zingoni; Angela Tincani; Silvano Sozzani; Daniela Bosisio
Journal:  JCI Insight       Date:  2018-05-17

Review 8.  The real culprit in systemic lupus erythematosus: abnormal epigenetic regulation.

Authors:  Haijing Wu; Ming Zhao; Christopher Chang; Qianjin Lu
Journal:  Int J Mol Sci       Date:  2015-05-15       Impact factor: 5.923

Review 9.  HDAC inhibitors and immunotherapy; a double edged sword?

Authors:  Michiel Kroesen; Paul Gielen; Ingrid C Brok; Inna Armandari; Peter M Hoogerbrugge; Gosse J Adema
Journal:  Oncotarget       Date:  2014-08-30

Review 10.  Breakdown of Immune Tolerance in Systemic Lupus Erythematosus by Dendritic Cells.

Authors:  Xiaofeng Liao; Alec M Reihl; Xin M Luo
Journal:  J Immunol Res       Date:  2016-02-29       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.